Director at Avalo Therapeutics (AVTX) exercises 3,166 RSUs into common stock

Rhea-AI Filing Summary

Avalo Therapeutics director Mitchell Chan exercised restricted stock units that vested into common shares. On March 28, 2026, 3,166 restricted stock units converted into 3,166 shares of common stock at a conversion price of $0.00 per share.

Following the transaction, Chan directly owned 6,333 shares of Avalo Therapeutics common stock. The restricted stock units convert into common stock on a one-for-one basis and are part of a 9,500-unit grant that vests in three equal annual installments starting March 28, 2025.

Insider Trade Summary

3,166 shares exercised/converted

Mixed 2 txns

Insider Chan Mitchell

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	3,166	$0.00	--
Exercise	Common Stock	3,166	$0.00	--

Holdings After Transaction: Restricted Stock Units — 3,167 shares (Direct); Common Stock — 6,333 shares (Direct)

Footnotes (1)

1. Restricted stock units convert into common stock on a one-for-one basis. On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.

Key Figures

RSUs exercised: 3,166 units Common shares received: 3,166 shares Post-transaction holdings: 6,333 shares +1 more

4 metrics

RSUs exercised 3,166 units Restricted stock units converted on March 28, 2026

Common shares received 3,166 shares One-for-one RSU-to-common stock conversion

Post-transaction holdings 6,333 shares Common stock directly owned after conversion

RSU grant size 9,500 units Awarded on August 13, 2024

Key Terms

Restricted Stock Units, derivative security, vest, one-for-one basis

4 terms

Restricted Stock Units financial

"Restricted stock units convert into common stock on a one-for-one basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vest financial

"vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

one-for-one basis financial

"Restricted stock units convert into common stock on a one-for-one basis."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chan Mitchell

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/28/2026		M		3,166	A	(1)	6,333	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/28/2026		M			3,166	(2)	(2)	Common Stock	3,166	$0	3,167	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Avalo Therapeutics (AVTX) report for Mitchell Chan?

Avalo Therapeutics reported that director Mitchell Chan exercised 3,166 restricted stock units into 3,166 common shares. The units converted at $0.00 per share, increasing his direct ownership to 6,333 common shares after the transaction.

How many Avalo Therapeutics (AVTX) shares does Mitchell Chan hold after this Form 4?

After the reported transaction, Mitchell Chan holds 6,333 shares of Avalo Therapeutics common stock directly. This reflects the addition of 3,166 newly issued shares from vested restricted stock units that converted on March 28, 2026 at a $0.00 conversion price.

What was the size and structure of Mitchell Chan’s RSU grant at Avalo Therapeutics (AVTX)?

Mitchell Chan received a grant of 9,500 restricted stock units on August 13, 2024. The award vests in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, subject to his continued service with Avalo Therapeutics on each vesting date.

At what price did Mitchell Chan’s Avalo Therapeutics (AVTX) RSUs convert into common stock?

The 3,166 restricted stock units converted into common stock at a price of $0.00 per share. This is typical for equity awards where the value is compensation-based, so Chan did not pay cash to receive the 3,166 newly issued common shares.

Does Mitchell Chan’s Avalo Therapeutics (AVTX) Form 4 show any stock sales?

The Form 4 shows only an exercise or conversion of restricted stock units into 3,166 common shares, with no reported sales. Both transactions are coded “M” for derivative exercise and are classified as acquisitions, increasing his direct common stock holdings.

How do Avalo Therapeutics (AVTX) restricted stock units convert into common stock?

Avalo Therapeutics restricted stock units convert into common stock on a one-for-one basis. In this filing, 3,166 restricted stock units became 3,166 common shares when they vested, consistent with the stated one-for-one conversion rate for this equity award.